Basal L-[ H]citrulline increased following aspirin 800 mg administered intravenously in vivo, from 0.3160.12 to 0.7660.14 pmol / 10 platelets (P,0.01). Isoproterenol at 1 mmol / l increased platelet NOS activity before but not following intravenous aspirin. After 3 short-term in vitro treatment with aspirin 10 mmol / l, 400 mmol / l or 4 mmol / l, basal platelet L-[ H]citrulline increased similarly, an effect not seen with indomethacin 100 mmol / l or ibuprofen 10 mmol / l. Platelet NOS activity was not increased by albuterol 1 mmol / l, in the presence of indomethacin, ibuprofen or aspirin in vitro. By contrast, oral aspirin 75 mg daily for 14 days did not affect basal platelet NOS activity, but abolished b-adrenergic NOS activation. Conclusions: Aspirin activates basal platelet NOS acutely, but not chronically, through a mechanism independent of cyclooxygenase (COX) inhibition. By contrast, both short-and long-term aspirin treatment inhibit platelet b-adrenergic NOS activation by a COX-dependent mechanism. This indicates that aspirin exerts divergent effects on basal and b-AR-stimulated platelet NOS activity, which are likely to be of clinical relevance.
. Introduction
endothelium [4] through activation of soluble guanylyl cyclase and consequent elevation in cGMP. Platelet-deHuman platelets synthesise nitric oxide (NO) through rived NO may also play an important role in regulation of the action of the enzyme nitric oxide synthase (NOS), both platelet recruitment and platelet aggregation after a which catalyses the oxidation of the terminal guanidino pro-aggregatory stimulus [5] . nitrogen atom of L-arginine to form L-citrulline [1] . Two of b-Adrenoceptors (b-AR) are present on human platelets the three known isoforms of NOS are found in platelets:
and have been characterised to be of the b -subtype as 2 endothelial (eNOS, NOS3) and inducible (iNOS, NOS2) determined by radioligand binding [6, 7] . They are coupled types [2, 3] , with NOS 3 being predominant. NO has to adenylyl cyclase and, when activated, cause an increase important antithrombotic properties including inhibition of in intracellular cAMP concentration leading to inhibition platelet aggregation [3] and of platelet adhesion to vascular of platelet aggregation [8] . We have recently demonstrated a link between b-AR and NOS activity in human platelets [9] . b -AR stimulation activates NOS through cAMP elevation, and this action is responsible for mediating endothelium undergoes minimal exposure to aspirin due to inhibition of platelet adhesion to vascular endothelium in its extensive pre-systemic hepatic metabolism, whereas response to b -adrenergic activation.
platelets in the portal circulation undergo much greater 2 In addition to NOS, platelets express cyclooxygenase exposure. We investigated the effects both of high-dose type 1 (COX-1), which catalyses the conversion of arachintravenous aspirin in vivo and of low-and high-conidonic acid to thromboxane A and other eicosanoids.
centration aspirin in vitro, in platelets. We also examined 2 Thromboxane A is a potent stimulus for platelet aggregathe effects of chronic oral low-dose aspirin on platelet 2 tion and a potent vasoconstrictor, in contrast to pros-NOS activity. In our studies, we used b-AR agonists as tacyclin (an endothelium-derived eicosanoid), which opstimulators of the L-arginine / NO system, since we have poses these effects by inhibiting platelet aggregation and previously demonstrated that b -AR activate NOS to an 2 acting as a vasodilator. important degree in platelets, an effect which gives rise to In disease states, the equilibrium between the detrimeninhibition of platelet adhesion to vascular endothelial cells tal effects of thromboxane A and the beneficial effects of [9] . 2 prostacyclin on the cardiovascular system may be disturbed. Impaired endothelium-dependent inhibition of platelet aggregation occurs in patients with atherosclerotic 2 . Methods disease [10] , and reduced basal platelet NO production has been found in patients with acute coronary syndrome [11] .
2 .1. Subjects The anti-platelet agent aspirin has become widely used clinically in view of its demonstrated mortality and Studies were performed on healthy normotensive submorbidity benefits in patients with acute myocardial infarcjects who gave written informed consent. All subjects took tion [12] , acute coronary syndrome [13] , acute cerebrovasno medications (and, in particular, had taken no anticular events [14] and following coronary artery bypass platelet agents for at least 14 days prior to study), were graft surgery [15] . These effects are largely ascribed to the aged 24-60 years, and underwent a complete history and ability of aspirin to acetylate irreversibly the serine 529 laboratory tests to exclude diabetes, renal, hepatic and residue in COX-1 preventing the formation of thromboxhematological disease. Blood samplings for all experiane A [16] . However, COX inhibition may decrease NOS 2 ments were performed after breakfast, between 09:00 and activity in healthy human platelets [17] , and aspirin has 11:00 h. The investigation conformed with the principles been shown to inhibit NOS 2 expression in the infarcted outlined in the Declaration of Helsinki (Cardiovasc Res rabbit heart [18] . By contrast, other workers have reported 1997;35:2-3), and all experiments were approved by the that aspirin can increase NO generation from leucocytes, St. Thomas' Hospital Local Research Ethics Committee. and can increase nitrite / nitrate concentration (an index of whole body NO generation) in the plasma [19] .
2 .2. Study 1: effect of acute high-dose aspirin In view of the close relationship between the NOS and administration on basal and b-AR-stimulated NOS COX systems, the conflicting evidence regarding the activity in platelets effects of aspirin on the NO system, the widespread use of aspirin in the treatment of cardiovascular disease and the Eight healthy male subjects took part in this study. importance of platelet NO production in the regulation of Subject characteristics are detailed in Table 1 . Platelets platelet function, the aim of the present study was to were isolated from 60 ml of venous blood, counted and explore further the effects of aspirin on the L-arginine / NO used for measurement of both basal and b-AR stimulated pathway in healthy human platelets both under basal and NOS activity. Platelet aliquots (1 ml) were incubated with stimulated conditions. In the treatment of patients with The platelet count in the eluate was (800 mg) dissolved in 20 ml of sterile saline was then measured using a Coulter counter. Eluates were used for administered at a rate of 1.5 ml / min via an intravenous NOS activity assay if platelet concentration was greater 11 cannula, which had been inserted at the start of the study. than 10 / l. A further venous blood sample (60 ml) was drawn 1 h after aspirin administration, platelets were isolated and the 2 .6. Determination of platelet NOS activity platelet NOS activity experiments repeated as before.
NOS activity in platelets was assessed by measuring the 3 3 2 .3. Study 2: effect of aspirin on basal and
citrulline as previstimulated NOS activity in platelets in vitro ously described [9] . Platelet suspensions (volume 1 ml) 3 were incubated with 1.0 mCi L-[ H]arginine in the absence Eleven healthy male and 10 healthy female subjects or presence of appropriate agonists and / or antagonists, as participated in this study (Table 1 ). Platelets were isolated described for each study. The reaction was terminated by G from 100 ml of venous blood, counted and used for addition of ice-cold Tyrodes buffer containing N -nitro-Lmeasurement of both basal and b-AR stimulated NOS arginine methyl ester (L-NAME) 100 mmol / l. Platelets activity. Platelet aliquots (1 ml) were first incubated with were pelleted at 20003g for 20 min, following which they either aspirin 10 mmol / l, aspirin 400 mmol / l, aspirin 4 were lysed by addition of 1 ml perchloric acid (0.3 mol / l) mmol / l, indomethacin 100 mmol / l (stock solution made and sonication for 30 min. Eight healthy male and four healthy female subjects 2 .7. Materials and drugs were enrolled in this study (Table 1) . Platelet NOS activity was measured before and after each subject had taken 75
Sepharoseீ CL-2B Gel was obtained from Amersham mg of aspirin orally for each of 14 consecutive days. 
.5. Isolation of platelets
All platelet NOS activity experiments were performed in triplicate and the mean of each triplicate was used for Venous blood (60-100 ml) was collected into trisodium further statistical analysis. Data were analysed using paired citrate (0.38% w / v final concentration). Platelet-rich plast-test or repeated measures ANOVA as appropriate (Graph ma (PRP), prepared by centrifugation (8003g for 8 min), Pad Prism version 3 software), and statistical significance was passed through a Sepharoseீ CL-2B Gel column.
was taken as P,0.05 (two-tailed). All data are expressed Platelets were eluted with, and collected in, calcium-free as mean6S.E.M. Platelet NOS activity was again assessed from the eight healthy subjects before and after acute systemic conversion of radiolabelled L-arginine to L-citrulline, in aspirin exposure (800 mg intravenously). Basal NOS platelets from healthy subjects. In response to incubation activity was significantly increased following aspirin adof platelets with three different concentrations of aspirin ministration, from 0.3160.12 to 0.7660.14 pmol L-citrul-(10 mmol / l, typical of the plasma concentrations found in 8 line / 10 platelets (P,0.01, Fig. 1A) . We have previously patients taking 75-80 mg aspirin per day orally, and 400 demonstrated that b-AR stimulation increases platelet NOS mmol / l and 4 mmol / l, both well above plasma conactivity [9] . In accordance with these findings, isocentrations found in patients treated with aspirin orally at a proterenol 1 mmol / l increased platelet L-citrulline prodosage of 325 mg daily or less), basal L-citrulline production significantly above basal, before aspirin treatment; duction was significantly increased as compared with that in the absence of aspirin ( Fig. 2A-C) . By contrast, no such effect was observed following incubation with two other COX inhibitors, indomethacin 100 mmol / l (Fig. 2D ) and ibuprofen 10 mmol / l (Fig. 2E) . The increase in basal NOS activity with aspirin ranged from approximately 30 to 60% (depending on the concentration of aspirin used). For comparison, we also examined the effect of collagen 8 mg / ml on platelet NOS in six subjects. Collagen increased platelet NOS activity by 96.3265.82% above basal (P, 0.05 as compared with all concentrations of aspirin). Therefore, the stimulation of NOS activity by aspirin was submaximal.
As predicted from our previous work [9] , stimulation of b -AR with albuterol 1 mmol / l increased platelet L-citrul-2 line production significantly above basal (P,0.002 for each), in the absence of aspirin or indomethacin. In the presence of 10 mmol / l or 400 mmol / l aspirin, albuterol produced no further rise in NOS activity above basal ( Fig.  2A,B) . In the presence of 4 mmol / l aspirin, albuterolmediated NOS activity actually decreased from basal (Fig.  2C) . The rise in albuterol-mediated L-citrulline production was similarly abolished by incubation with indomethacin 100 mmol / l (Fig. 2D) or ibuprofen 10 mmol / l (Fig. 2E) .
In a subset of our subjects (n55), we determined the effect of aspirin 10 mmol / l, 400 mmol / l and 4 mmol / l, and of albuterol 1 mmol / l, on platelet cGMP using a proprietary radioimmunoassay kit (Amersham Biosciences, 8 UK). Basal cGMP was 2.4460.26 pmol / 10 platelets; this increased significantly in response to each concentration of 8 aspirin (3.4260.22, 3.1060.34 and 3.2660.44 pmol / 10 platelets for 10 mmol / l, 400 mmol / l and 4 mmol / l aspirin, respectively, P,0.05 for each) and to albuterol 8 (3.6160.48 pmol / 10 platelets, P,0.05), thus confirming that the increase in NOS activity in response to these agents was mirrored by an increase in cGMP (an index of We also determined whether inhibition of cAMP synproterenol-stimulated NOS activity before and after aspirin administration. *P,0.01 as compared with basal response before aspirin exposure. thesis blocked the increase in platelet NOS activity in response to aspirin 10 mmol / l, 400 mmol / l and 4 mmol / l, 0.4060.06 and 0.3960.05 pmol / 10 platelets for 10 and to albuterol 1 mmol / l. For this purpose, the effect of mmol / l, 400 mmol / l and 4 mmol / l aspirin, respectively), SQ22536 50 mmol / l (a specific membrane-permeable demonstrating that the stimulant effect of aspirin on NOS adenylyl cyclase inhibitor) on platelet NOS activity in activity, unlike that of b -adrenergic stimulation, was not 2 response to these agents was determined in a subset of our dependent on adenylyl cyclase stimulation. subjects (n55). Basal L-citrulline formation was To this end, we treated healthy subjects (n512) with SQ22536), but did not suppress L-citrulline formation in aspirin 75 mg orally daily (a low dose which is commonly response to any concentration of aspirin (0.3960.06, used clinically for cardiovascular protection) for 14 days. Platelet NOS activity was measured both before and after this period of treatment. In contrast to our findings with acute aspirin exposure, there was no significant effect of chronic low-dose aspirin therapy on basal NOS activity 8 (0.3160.06 before vs. 0.3860.08 pmol L-citrulline / 10 platelets after aspirin therapy, Fig. 3A) . In response to isoproterenol 1 mmol / l or albuterol 1 mmol / l, platelet NOS activity increased as before, in subjects before aspirin treatment (Fig. 3B) . However, following 14 days of aspirin therapy, the increase in response to either b-AR agonist was abolished.
. Discussion
These studies have highlighted differences in the effects of acute and chronic aspirin exposure on platelet NOS activity. Acute high-dose exposure of platelets to aspirin in vivo following intravenous injection activates basal NOS activity. Similarly, in vitro incubation of platelets with aspirin at three different concentrations (10 mmol / l, representative of plasma levels found during aspirin treatment at the low doses used in cardiovascular disease prophylaxis [20] ; 400 mmol / l, which is representative of plasma levels obtained during aspirin treatment at anti-inflammatory doses or during intravenous infusion of aspirin at the dosage used in our study [21] ; and 4 mmol / l, which is within the range of plasma concentration found in patients with aspirin toxicity) increases NOS activity basally. This acute stimulatory effect of aspirin on NOS is not shared by indomethacin or ibuprofen. Although this study cannot exclude a small stimulatory effect of indomethacin or ibuprofen on NOS, such an effect-if present-would be experiments, on NOS 3 expression or NOS 3 phosphorylaconcentrations [20] . Although our study cannot exclude a tion in platelets, as determined by immunoprecipitation of small stimulatory effect of chronic low-dose aspirin NOS 3 and Western blotting (data not shown).
therapy on basal platelet NOS activity, any such effect-if Chen et al. have previously reported that aspirin and present-would be considerably smaller than that observed indomethacin both decrease NOS activity and nitrite / nifollowing acute aspirin exposure. trate formation in platelets [17] . However, de la Cruz et al.
Our findings suggest that aspirin exerts two types of found that aspirin increases NO production from neutroeffect on platelet NOS, depending on the length of phils and elevates plasma nitrite / nitrate [19] . The reasons treatment. After both short-and long-term treatment, it for discrepancies between results from different groups is inhibits b-AR-mediated NOS activation, and the fact that unclear, but may relate to differences in the platelet indomethacin and ibuprofen cause a similar effect suggests preparation procedure; in particular, high-speed centrifugathat this is secondary to COX inhibition, although the tion of PRP may increase platelet activation basally, giving mechanism by which COX inhibition may affect stimurise to an artificially high basal NOS activity, and such lated NOS activity remains to be determined. After acute platelet activation will be reduced by COX inhibition. Our exposure, at both low and high concentration, aspirin can method of platelet isolation from PRP, namely Sepharose also stimulate basal platelet NOS activity, and this effect is gel filtration, is much less likely to cause platelet activation COX-independent. b-AR-mediated inhibition of adhesion basally. Our data suggest that, in fact, aspirin at both low and aggregation in platelets may be important clinically as and high concentration activates platelet NOS acutely. In this may partially offset the pro-aggregatory effects of contrast, we found that b-AR agonists failed to increase a-adrenoceptor stimulation in response to the endogenous NOS activity in platelets exposed to aspirin, both in vivo catecholamines norepinephrine and epinephrine [22] . At and in vitro. It might be argued that, since aspirin rest, the circulating plasma concentrations of norepinephstimulates NOS activity basally, no further increase in rine and epinephrine range between 0.3-3.0 and 0.1-0.5 NOS activity could occur in response to b-adrenergic nmol / l, respectively, which are lower than the reported stimulation. However, this is unlikely to be the explanaaffinity of these catecholamines for b-AR [7, 8] . However, tion, for two reasons. First, we found that NOS activity in times of stress, in particular during acute coronary could be increased by almost 100% in response to collagen syndrome and myocardial infarction, these levels may 8 mg / ml, whereas it was only increased by 30-60% by increase to more than 10 nmol / l [23] , concentrations aspirin. Second, in vitro, we found that b-AR stimulation sufficient to induce significant activation of b-AR on failed to activate NOS in platelets exposed to two other platelets. Thus, effects of aspirin on b-AR-mediated COX inhibitors, indomethacin and ibuprofen, despite no platelet NOS activation may be of clinical relevance; this change in basal NOS activity in the presence of these remains to be determined. Large clinical trials have drugs. Therefore, unlike its effect on basal NOS activity, repeatedly shown that long-term aspirin confers carthe effect of aspirin on b-adrenergic NOS activation diovascular protection in those patients at risk of thromappears to be mediated through COX inhibition.
boembolic disease [24] , implying that the effects on COX In contrast to the activating effect of acute aspirin on outweigh any adverse effect of inhibition of b-AR-meplatelet NOS, we found that 2 weeks of low-dose (75 mg) diated NOS activation. However, a substantial number of oral aspirin therapy did not significantly affect basal patients develop recurrent cardiovascular events despite platelet NOS activity. On the other hand, it did abolish aspirin therapy, suggesting that some patients may be at b-AR-mediated NOS activation, as did acute aspirin (or least partially aspirin resistant [25, 26] . Our findings with other COX inhibitor) exposure. This indicates that platelets regard to suppression of b-AR-mediated NOS activation exposed to aspirin chronically at low dose in vivo behave following chronic low-dose aspirin therapy may be of differently to those exposed to the drug acutely, with relevance to this phenomenon, but this needs further regard to basal NOS activity, although the mechanism investigation. underlying this effect is unclear at present. We used a dose
In conclusion, we have demonstrated that aspirin, in of 75 mg aspirin once daily in this study, since this reflects vivo and in vitro, can activate platelet NOS acutely by a the dosage typically used in patients long-term for carmechanism that is independent of COX inhibition. In diovascular prophylaxis, and therefore the results are contrast, chronic aspirin treatment, at a low dose commonreadily applicable to the clinical situation. Such a dose ly used clinically for cardiovascular prophylaxis (75 mg gives rise to plasma levels in the micromolar range, which daily), does not affect basal platelet NOS activity. Expoare much lower than those attained using 800 mg intravensure of platelets to aspirin both at high and low conously (as used in study 1). We performed our measurecentration, and acutely as well as chronically, impairs ments of platelet NOS activity after 14 days treatment of b-AR-mediated NOS activation, and this effect is exerted subjects with low-dose oral aspirin, rather than after single through COX inhibition. Further studies are needed to dose treatment, since it is known that one single oral dose determine the cellular mechanisms and clinical conseof 75 mg aspirin gives rise to extremely low plasma quences of these effects.
